drugset / Trial / NCT03282318

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis

NCT03282318 ↗

Phase 2 Completed 119 enrolled Astellas Pharma Europe B.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). This study will also investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of ASP6294 in female participants with BPS/IC.

Timeline

Start
2017-09-28
Primary completion
2019-03-21
Completion
2019-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP6294 Unknown 320 mg Subcutaneous

Indications